Findings

What do systematic reviews say?

102 questions · 102 findings · 46 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 56 · 54.9%GRADE not reported 10 · 9.8%Very low 14 · 13.7%Low 15 · 14.7%Moderate 4 · 3.9%High 3 · 2.9%

Summary of findings table ‐ Platinum‐sensitive recurrent EOC: PARPi monotherapy vs placebo (maintenance therapy)

QoL · platinum‐sensitive recurrent EOC

1 finding from 1 review

Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer 2022 · Cochrane Headline outcomes only
no estimate extracted
1 study · 339 participants
Moderate

ALK inhibitor vs any cytotoxic chemotherapy

Health‐related quality of life: time to deterioration in composite endpoint (cough, dyspnoea, and chest pain) · advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer

ALK inhibitor leads to lower health‐related quality of life: time to deterioration in composite… compared with any cytotoxic chemotherapy (high certainty).

1 finding from 1 review

Targeted therapy for advanced anaplastic lymphoma kinase (ALK)‐rearranged non‐small cell lung cancer 2022 · Cochrane Headline outcomes only
HR 0.52 [0.44, 0.6]
5 studies · 1504 participants
High